NCT00982930View on ClinicalTrials.gov

Open Label Extension to Bridging Study CTBM100C2303

PHASE3CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

August 12, 2009

Primary Completion Date

October 31, 2011

Study Completion Date

October 6, 2011

Conditions
Pseudomonas AeruginosaCystic Fibrosis
Interventions
DRUG

Tobramycin inhalation powder

Tobramycin inhalation powder, 112 mg (4 capsules of 28 mg), inhalation capsules, b.i.d.

Trial Locations (2)

Unknown

Novartis Investigative Site, Tallinn

Novartis Investigative Site, Yaroslavl

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY